Anticancer hybrids- a patent survey

Kunal Nepali, Sahil Sharma, Dinesh Kumar, Abhishek Budhiraja, Kanaya L. Dhar

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The molecular hybridization (MH) is a strategy of rational design of such ligands or prototypes based on the recognition of pharmacophoric sub-units in the molecular structure of two or more known bioactive derivatives which, through the adequate fusion of these sub-units, lead to the design of new hybrid architectures that maintain pre-selected characteristics of the original templates. The concept of molecular hybridization and the promises/challenges associated with these hybrid molecules along with recent advances on anticancer hybrids and critical discussions on the future aspects of the hybrid drugs have already been presented through a number of reports. However, this article presents the structures of potent hybrids reported during the last two decades along with a detailed account of the patent literature. Significant number of patents on the molecules designed through this valuable drug design technique clearly highlight the present focus of the researchers all around the globe towards hybrid molecules capable of amplifying the effect of individual functionalities through action on another bio target or to interact with multiple targets as one single molecule lowering the risk of drug-drug interactions and minimizing the drug resistance. This review article basically emphasizes the patent literature along with an overview of potent hybrid structures, their IC50 /GI50 values against the various cell lines employed. The present compilation can be utilized as a guide for the medicinal chemists focusing on this area of drug design.

Original languageEnglish
Pages (from-to)303-339
Number of pages37
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume9
Issue number3
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Patents
Literature
Drug Design
Molecular Structure
Drug Interactions
Drug Resistance
Pharmaceutical Preparations
Inhibitory Concentration 50
Research Personnel
Ligands
Cell Line
Surveys and Questionnaires

Keywords

  • Anticancer
  • Design
  • Drug
  • Hybrids
  • Microtubule
  • Steroids

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Cancer Research
  • Pharmacology (medical)

Cite this

Anticancer hybrids- a patent survey. / Nepali, Kunal; Sharma, Sahil; Kumar, Dinesh; Budhiraja, Abhishek; Dhar, Kanaya L.

In: Recent Patents on Anti-Cancer Drug Discovery, Vol. 9, No. 3, 01.01.2014, p. 303-339.

Research output: Contribution to journalReview article

Nepali, Kunal ; Sharma, Sahil ; Kumar, Dinesh ; Budhiraja, Abhishek ; Dhar, Kanaya L. / Anticancer hybrids- a patent survey. In: Recent Patents on Anti-Cancer Drug Discovery. 2014 ; Vol. 9, No. 3. pp. 303-339.
@article{ca8621b0eb6c4d80a68f5b3d89669a1d,
title = "Anticancer hybrids- a patent survey",
abstract = "The molecular hybridization (MH) is a strategy of rational design of such ligands or prototypes based on the recognition of pharmacophoric sub-units in the molecular structure of two or more known bioactive derivatives which, through the adequate fusion of these sub-units, lead to the design of new hybrid architectures that maintain pre-selected characteristics of the original templates. The concept of molecular hybridization and the promises/challenges associated with these hybrid molecules along with recent advances on anticancer hybrids and critical discussions on the future aspects of the hybrid drugs have already been presented through a number of reports. However, this article presents the structures of potent hybrids reported during the last two decades along with a detailed account of the patent literature. Significant number of patents on the molecules designed through this valuable drug design technique clearly highlight the present focus of the researchers all around the globe towards hybrid molecules capable of amplifying the effect of individual functionalities through action on another bio target or to interact with multiple targets as one single molecule lowering the risk of drug-drug interactions and minimizing the drug resistance. This review article basically emphasizes the patent literature along with an overview of potent hybrid structures, their IC50 /GI50 values against the various cell lines employed. The present compilation can be utilized as a guide for the medicinal chemists focusing on this area of drug design.",
keywords = "Anticancer, Design, Drug, Hybrids, Microtubule, Steroids",
author = "Kunal Nepali and Sahil Sharma and Dinesh Kumar and Abhishek Budhiraja and Dhar, {Kanaya L.}",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/1574892809666140520150459",
language = "English",
volume = "9",
pages = "303--339",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Anticancer hybrids- a patent survey

AU - Nepali, Kunal

AU - Sharma, Sahil

AU - Kumar, Dinesh

AU - Budhiraja, Abhishek

AU - Dhar, Kanaya L.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The molecular hybridization (MH) is a strategy of rational design of such ligands or prototypes based on the recognition of pharmacophoric sub-units in the molecular structure of two or more known bioactive derivatives which, through the adequate fusion of these sub-units, lead to the design of new hybrid architectures that maintain pre-selected characteristics of the original templates. The concept of molecular hybridization and the promises/challenges associated with these hybrid molecules along with recent advances on anticancer hybrids and critical discussions on the future aspects of the hybrid drugs have already been presented through a number of reports. However, this article presents the structures of potent hybrids reported during the last two decades along with a detailed account of the patent literature. Significant number of patents on the molecules designed through this valuable drug design technique clearly highlight the present focus of the researchers all around the globe towards hybrid molecules capable of amplifying the effect of individual functionalities through action on another bio target or to interact with multiple targets as one single molecule lowering the risk of drug-drug interactions and minimizing the drug resistance. This review article basically emphasizes the patent literature along with an overview of potent hybrid structures, their IC50 /GI50 values against the various cell lines employed. The present compilation can be utilized as a guide for the medicinal chemists focusing on this area of drug design.

AB - The molecular hybridization (MH) is a strategy of rational design of such ligands or prototypes based on the recognition of pharmacophoric sub-units in the molecular structure of two or more known bioactive derivatives which, through the adequate fusion of these sub-units, lead to the design of new hybrid architectures that maintain pre-selected characteristics of the original templates. The concept of molecular hybridization and the promises/challenges associated with these hybrid molecules along with recent advances on anticancer hybrids and critical discussions on the future aspects of the hybrid drugs have already been presented through a number of reports. However, this article presents the structures of potent hybrids reported during the last two decades along with a detailed account of the patent literature. Significant number of patents on the molecules designed through this valuable drug design technique clearly highlight the present focus of the researchers all around the globe towards hybrid molecules capable of amplifying the effect of individual functionalities through action on another bio target or to interact with multiple targets as one single molecule lowering the risk of drug-drug interactions and minimizing the drug resistance. This review article basically emphasizes the patent literature along with an overview of potent hybrid structures, their IC50 /GI50 values against the various cell lines employed. The present compilation can be utilized as a guide for the medicinal chemists focusing on this area of drug design.

KW - Anticancer

KW - Design

KW - Drug

KW - Hybrids

KW - Microtubule

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=84905637758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905637758&partnerID=8YFLogxK

U2 - 10.2174/1574892809666140520150459

DO - 10.2174/1574892809666140520150459

M3 - Review article

VL - 9

SP - 303

EP - 339

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 3

ER -